ArticleThe American journal of medicine2025
Outcomes of Oral Anticoagulation with Concomitant NSAID Use: A Registry Based Cohort Study.
Article in The American journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of monthly bleeding rates after direct oral anticoagulant initiation for venous thromboembolism and atrial fibrillation.Research and practice in thrombosis and haemostasis · 2026Article
- Article
- Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundConcomitant use of oral anticoagulants (OACs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is common despite concerns about increased bleeding risk. We sought to assess the frequency of co-administering NSAIDs for patients on OAC and the impact on clinical outcomes.
methodsWe conducted a multicenter registry-based cohort study, utilizing 4:1 propensity score matching to compare patients on OAC monotherapy to those on OAC+NSAIDs therapy between 2011 and 2023 at six anticoagulation clinics of the Michigan Anticoagulation Quality Improvement Initiative. Adults on OAC for venous thromboembolism and/or atrial fibrillation were included. Patients with a history of heart valve replacement, under 3 months of follow-up, or using two or more antiplatelet drugs were excluded. The primary outcome was any bleeding. Secondary outcomes included bleeding subtypes, thrombosis/thromboembolism, healthcare utilization, and mortality.
resultsAmong the 12,083 patients receiving OAC, 449 (3.7%) were concurrently prescribed NSAIDs. The 1,796 patients on OAC monotherapy were compared to 449 patients on OAC+NSAID therapy after propensity matching. The matched groups were well balanced and followed for an average of 30 months. No significant differences were observed in bleeding event rates per 100 patient-years between the two groups, including overall (25.1 vs. 24.3, p= 0.56), major, and non-major bleeding. Rates of thrombosis, emergency room visits, hospitalizations, transfusion, and mortality were also similar.
conclusionClinical outcomes were similar between OAC monotherapy and OAC with concomitant NSAIDs use in this real-world observational study. As there are limited treatment options for pain, further prospective research should be conducted to replicate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.